unfractioned heparin
- heparin (anticoagulant)
- non specific binding
- increases AT-III activity
enoxaparin
- LMW heparin (anticoagulant)
- increases AT-III activity (X > thrombin)
dalteparin
- LMW heparin (anticoagulant)
- increases AT-III activity (X > thrombin)
fondaparinux
- heparin derived (anticoagulant)
- pure Xa inhibitor (thru AT-III)
lepiruidin
- direct thrombin inhibitor (anticoagulant)
- AT-III independent
- binds thormbin:fibrin complex
- hepatic clearance
argatroban
- direct thrombin inhibitor (anticoagulant)
- renal clearance
dabigatran
- direct thrombin inhibitor (anticoagulant)
- renal clearance
rivaroxaban
- direct factor Xa inhibitor (anticoagulant)
- renal clearance
recombinant tPA
- thrombolytic (anticoagulant)
- converts plasminogen to plasmin, which degrades clot
warfarin
- vitamin K antagonist (anticoagulant)
- blocks factors: 2, 7, 9, 10, protein C/S
aspirin
- anti platelet agent (anticoagulant)
- irreversibly inhibits COX2
- decreased thromboxane
- impaired aggregation
clopidogrel
- anti platelet agent (anticoagulant)
- irreversibly inhibits PGY12 receptor of ADP
- inhibits platelet aggregation
prasugrel
- anti platelet agent (anticoagulant)
- rapid onset
NSAID
- anti platelet agent (anticoagulant)
- reversibly inhibits COX2
- decreased thromboxane
- inhibits platelet aggregation
abciximab
- GPIIb/IIIa antagonist (anticoagulant)
- reversibly inhibits platelet aggregation
- binding site of fibrinogen between platelets
vorapaxar
- PAR-1 antagonist (anticoagulant)
- blocks thrombin related platelet aggregation
dipyridamole
-PDE5 inhibitor (anticoagulant)
-PDE normally breaks down cAMP
(increased cAMP decreases platelet aggregation response to ADP)
vitamin K
- pro coagulant
- promotes production of factors 2, 7, 9, 10, protein C/S
recombinant factor VIIa
- pro coagulant
- extrinsic pathway
desmopressin acetate (DDAVP)
-promotes release of stored vWF from vascular endothelium
aminocaproic acid
- anti fibrinolytic
- used in management of bleeds as a result of thrombolytic therapy
